Document Detail

Emerging drugs in psoriasis.
MedLine Citation:
PMID:  15989537     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Psoriasis is a relatively common, chronic skin disease affecting 1-2% of the population in the developed countries. It is an inflammatory, autoimmune skin disorder characterised by an accelerated rate of epidermal proliferation and disordered differentiation. Since our last review in 1999, considerable progress has been made in understanding the immunopathogenesis of this disease, and new drugs have become available for its treatment. Recent clinical trials showed the efficacy of novel biotechnology approaches, such as blocking tumour necrosis factor-alpha or T-cell-mediated immune response by the anti-CD2, anti-CD11a, anti-B7, anti-CD4 or anti-CD25 approaches. Agents which block type 1 cytokines or skew immune reactions into type 2 are other promising approaches. Other possible targets are chemokines and their receptors, the cytokines and receptors involved in T cell trafficking into the skin, and peroxisome proliferator-activated receptors. Relatively little development is reported of the drugs targeting the keratinocyte or the classical antipsoriatic compounds which include glucocorticoids, vitamin D derivatives and cytostatic agents.
Robert Gniadecki; Martin J Calverley
Related Documents :
17305637 - Altered cd40 and e-cadherin expression--putative role in oral lichen planus.
18643847 - Mast cells determine the magnitude of bacterial toxin-induced skin inflammation.
6446017 - Effect of the adaptive response on the induction of the sos pathway in e. coli k-12.
19046297 - Reduced il-1ra/il-1 ratio in ultraviolet b-exposed skin of patients with polymorphic li...
15135897 - Nervous system injury: focus on the inflammatory cytokine 'granulocyte-macrophage colon...
17142747 - Phagocytosis induces lysosome remodeling and regulated presentation of particulate anti...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on emerging drugs     Volume:  7     ISSN:  1744-7623     ISO Abbreviation:  Expert Opin Emerg Drugs     Publication Date:  2002 May 
Date Detail:
Created Date:  2005-07-01     Completed Date:  2005-07-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101135662     Medline TA:  Expert Opin Emerg Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  69-90     Citation Subset:  -    
Department of Dermatology, Bispebjerg Hospital, DK-2400 Copenhagen NV, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Developments in the treatment of leishmaniasis and trypanosomiasis.
Next Document:  New and emerging treatments for irritable bowel syndrome and functional dyspepsia.